Effect of an insulin sensitizer, pioglitazone, on hypertension in fructose-drinking rats

Japanese Journal of Pharmacology

Volumn 74, Issue 4, 1997, Pages 297-302

  Suzuki, Masami ^a   Nomura, Chisako ^a   Odaka, Hiroyuki ^a   Ikeda, Hitoshi ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Fructose; Hyperinsulinemia; Hypertension; Insulin resistance; Pioglitazone

Indexed keywords

FRUCTOSE; GLUCOSE; INSULIN; PIOGLITAZONE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN RESPONSE; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PULSE RATE; RAT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0030823494     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.74.297     Document Type: Article

References (36)

1. Skarfors ET, Lithell HO and Selinus I: Risk factors for the development of hypertension: 10-year longitudinal study in middle-aged men. J Hypertens 9, 217-223 (1991)
2. Haffner SM, Ferrannini E, Hazuda HP and Stern MP: Clustering of cardiovascular risk factors in confirmed prehypertensive individuals. Hypertension 20, 38-45 (1992)
3. Lissner L, Bengtsson C, Lapidus L, Kristjansson K and Wedel H: Fasting insulin in relation to subsequent blood pressure changes and hypertension in women. Hypertension 20, 797-801 (1992)
4. Yamada N, Gotoda T, Yoshinaga H, Ohashi Y, Sakurai N, Yazaki Y, Shimano H and Kosaka K: Increased risk factors for coronary artery disease in Japanese subjects with hyper-insulinemia or glucose intolerance. Diabetes Care 17, 107-114 (1994)
5. Modan M, Halkin H, Almog S, Lusky A, Eskol A, Shefi M, Shirit A and Fuchs L: A link between hypertension, obesity and glucose intolerance. J Clin Invest 75, 809-817 (1985)
6. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, Pedrinelli R, Brandi L and Bevilacqua S: Insulin resistance in essential hypertension. N Engl J Med 317, 350-357 (1987)
7. Reaven GM: Role of insulin in human disease. Diabetes 37, 1595-1607 (1988)
8. Ferrari P, Weidmann P, Shaw S, Giachino D, Riesen W, Allemann Y and Heynen G: Altered insulin sensitivity, hyperinsulinaemia and dyslipidaemia in individuals with a hypertensive parent. Am J Med 91, 589-596 (1991)
9. DeFronzo RA, Cooke CR, Andres R, Faloona GR and Davis PJ: The effects of insulin on renal handling of sodium, potassium, calcium and phosphate in man. J Clin Invest 55, 845-855 (1975)
10. DeFronzo RA: The effect of insulin on renal sodium metabolism: a review with clinical implications. Diabetologia 21, 165-171 (1981)
11. Rowe JW, Young JB, Minaker KL, Stevens AL, Pallotta J and Landsberg L: Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes 30, 219-225 (1981)
12. Moreau P, Lamarche L, Laflamme AK, Calderone A, Yamaguchi N and de Champlain J: Chronic hyperinsulinaemia and hypertension: the role of the sympathetic nervous system. J Hypertens 13, 333-340 (1995)
13. Tobey TA, Mondon CE, Zavaroni I and Reaven GM: Mechanism of insulin resistance in fructose-fed rats. Metabolism 31, 608-612 (1982)
14. Ikeda H, Taketomi S, Sugiyama Y, Sohda T, Meguro K and Fujita T: Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arzneimittelforschung 40, 156-162 (1990)
15. Sugiyama Y, Shimura Y and Ikeda H: Effects of pioglitazone on hepatic and peripheral insulin resistance in Wistar fatty rats. Arzneimittelforschung 40, 436-440 (1990)
16. Sohda T, Momose Y, Meguro K, Kawamatsu Y, Sugiyama Y and Ikeda H: Studies on antidiabetic agents: Synthesis and hyperglycemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones. Arzneimittelforschung 40, 37-42 (1990)
17. Hwang IS, Ho H, Hoffman BB and Reaven GM: Fructose-induced insulin resistance and hypertension in rats. Hypertension 10, 512-516 (1987)
18. Ohno Y, Suzuki H, Yamakawa H, Nakamura M, Otsuka K and Saruta T: Impaired insulin sensitivity in young, lean normotensive offspring of essential hypertensives: possible role of disturbed calcium metabolism. J Hypertens 11, 421-426 (1993)
19. Lever AF: Slow pressor mechanisms in hypertension: a role for hypertrophy of resistance vessels. J Hypertens 4, 515-524 (1986)
20. Banskota NK, Taub R, Zellner K and King GL: Insulin, IGF-1 and PDGF interact additively in the activation of protooncogene c-myc and cellular proliferation in cultured bovine aortic smooth muscle cells. Mol Endocrinol 3, 1183-1190 (1989)
21. Nolan JJ, Ludvik B, Beerdsen P, Gumbiner B and Olefsky JM: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331, 1188-1193 (1994)
22. Ogihara T, Rakugi H, Ikegami H, Mikami H and Masuo K: Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertents 8, 316-320 (1995)
23. Kawaguchi M, Tanigawa K and Kato Y: A study of effect of CS-045, a new antidiabetic drug, on hypertension in spontaneously hypertensive rats. Endocrine J 42, 557-561 (1995)
24. Yoshioka S, Nishiro H, Shiraki T, Ikeda K, Koike H, Okuno A, Wada M, Fujiwara T and Horikoshi H: Antihypertensive effects of CS-045 treatment in obese Zucker rats. Metabolism 42, 75-80 (1993)
25. Dubey RK, Zhang HY, Reddy SR, Boegehold MA and Kotchen TA: Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. Am J Physiol 265, R726-R732 (1993)
26. Buchanan TA, Meehan WP, Jeng YY, Yang D, Chan TM, Nadler JL, Scott S, Rude RK and Hsueh WA: Blood pressure lowering by pioglitazone: evidence for a direct vascular effect. J Clin Invest 96, 354-360 (1995)
27. Zhang HY, Reddy SR and Kotchen TA: Antihypertensive effect of pioglitazone is not invariable associated with insulin sensitivity. Hypertension 24, 106-110 (1994)
28. Zhang F, Sowers JR, Ram JL, Standley PR and Peuler JD: Effects of pioglitazone in calcium channels in vascular smooth muscle. Hypertension 24, 170-175 (1994)
29. Kotchen TA, Zhang HY, Reddy S and Hoffmann RG: Effect of pioglitazone on vasuclar reactivity in vivo and in vitro. Am J Physiol 270, R660-R666 (1996)
30. Inui Y, Kawata S, Matsuzawa Y, Tokunaga K, Fujioka S, Tamura S, Kobatake T, Keno Y, Odaka H, Matsuo T and Tarui S: Inhibitory effect of a new α-glucosidase inhibitor on fatty liver in Zucker fatty rats. J Hepatol 10, 62-68 (1990)
31. y. J Nutr Sci Vitaminol 38, 27-37 (1992)
32. Kazumi T, Hirano T, Odaka H, Ebara T, Amano N, Hozumi T, Ishida Y and Yoshino G: VLDL triglyceride kinetics in Wistar fatty rats, an animal model of NIDDM. Diabetes 45, 806-811 (1996)
33. Sugiyama Y, Taketomi S, Shimura Y, Ikeda H and Fujita T: Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats. Arzneimittelforschung 40, 263-267 (1990)
34. Kanai H, Matsuzawa Y, Kotani K, Keno Y, Kobatake T, Nagai Y, Fujioka S, Tokunaga K and Tarui S: Close correlation of intra-abdominal fat accumulation to hypertension in obese women. Hypertension 16, 484-490 (1990)
35. Kanai H, Tokunaga K, Fujioka S, Yamashita S, Takemura K and Matsuzawa Y: Decrease in intra-abdominal visceral fat may reduce blood pressure in obese hypertensive women. Hypertension 27, 125-129 (1996)
36. Rebuffe-Scrive M, Andersson B, Olbe L and Bjorntorp P: Metabolism of adipose tissue in intraabdominal depots of nonobese men and women. Metabolism 38, 453-458 (1989)